Spring Valley’s monoclonal development program is divided into phases to provide ultimate flexibility. The standard program is outlined below. It can be customized to fit your needs. Decisions are made by the customer with input from SVL staff as needed.

Phase 1: (8-10 weeks)
Mice are immunized to obtain a pool of immune animals from which an animal(s) is selected for fusion.

Phase 2: (2 to 3 weeks)
The mouse (or mice) selected in Phase I is given a final boost. Spleen cells are then isolated and fused to NS-1 myeloma cells. Supernatant fluids from fused cells are evaluated for antibodies production.

Phase 3: (3 to 4 weeks)
The fused cells from Phase II that produce desired antibody(ies) are selected for cloning by limiting dilution. These clones are also evaluated for antibody production and then expanded into hybridoma cell lines and frozen.

Larger-scale antibody production

in vivo: ascites fluid in mice
Spring Valley can inject hybridoma cell lines into mice to produce ascitic fluid (ascites). Any hybridoma cell line can be used, whether or not Spring Valley produced it. All hybridoma cells lines need to be tested for the presence of extraneous murine viruses prior to being injected. Each mouse that is injected will produce between 0.5 ml and 5 ml of ascites depending upon the characteristics of the cell line.

in vitro: culture flasks
Spring Valley can produce monoclonal antibodies from your hybridoma using gas permeable bags or cell culture flasks.

Due to the inherent variability between immunogens, animals, and clones, Spring Valley does not guarantee the quality or specificity of the monoclonal antibody, the antibody yield from culture or ascites, or the final volume of ascites fluid.

Please contact us to discuss your particular needs. Let us help you.